IP Library Granted Patent US 8,629,129
Granted Patent B2
US 8,629,129 · App. 13/602,602 · Granted Jan 14, 2014

Pharmaceutical compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,629,129
App. No.
13/602,602
Granted
Jan 14, 2014
Kind
B2
Abstract

Novel methods for treating or reducing the likelihood of acquiring symptoms or diseases due to the menopause, in postmenopausal women, particularly osteoporosis, vaginal atrophy and dryness, hypogonadism, diminished libido, skin atrophy, connective tissue disease, urinary incontinence, breast, endometrial, ovarian and uterine cancers, hot flashes, loss of muscle mass, insulin resistance, fatigue, loss of energy, aging, physical symptoms of menopause, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor are disclosed. Said method comprising novel ways of administering and dosing dehydroepiandrosterone (DHEA) in order to take advantage of positive androgenic effects in the vaginal layers lamina propia and/or the layer muscularis, without undesirably causing systemic estrogenic effects in order to avoid the risk of breast and uterine cancer. Pharmaceutical compositions for delivery of active ingredient(s) useful to the invention are also disclosed.

Claims (8)

1. A finished pharmaceutical dosage form for human vaginal administration comprising sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone-sulfate, androst-5-ene-3β,17β-diol, and 4-androsten-3,17-dione wherein said precursor is present in said dosage form in an amount that does not exceed 13 milligrams;

wherein the precursor concentration is between 0.1 and 10% by weight relative to the total weight of the dosage form.

2. The dosage form of claim 1 wherein said dosage form is a vaginal suppository.

3. The dosage form of claim 1 wherein said sex steroid precursor is dehydroepiandrosterone.

4. The dosage form of claim 1 wherein said precursor is present in an amount from 3-13 milligrams.

5. The dosage form of claim 3 wherein said precursor is present in an amount from 3-13 milligrams.

6. The dosage form of claim 2 wherein said precursor is dehydroepiandrosterone.

7. The dosage form of claim 6 wherein said precursor is present in an amount from 3-13 milligrams.

Assignments (6)
COURT ORDER Recorded Aug 7, 2024
From: CRG SERVICING LLC
To: ENDORECHERCHE INC.
Reel/Frame 068480/0422 →
PATENT SECURITY AGREEMENT Recorded Jul 9, 2024
From: MYRIEL PHARMACEUTICALS, LLC
To: UBS AG, STAMFORD BRANCH, AS ADMINISTRATIVE AGENT
Reel/Frame 068257/0832 →
SECURITY INTEREST Recorded Jun 26, 2024
From: COSETTE PHARMACEUTICALS, INC.; MYRIEL PHARMACEUTICALS, LLC
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 067849/0095 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2023
From: ENDORECHERCHE INC.
To: MYRIEL PHARMACEUTICALS, LLC
Reel/Frame 063919/0913 →
SECURITY INTEREST Recorded Dec 15, 2016
From: ENDORECHERCHE INC.
To: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 040638/0249 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2013
From: LABRIE, FERNAND, DR.
To: ENDORECHERCHE, INC.
Reel/Frame 029562/0509 →